NCI UC13N01: Phase I/II trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer: Subproject for Institution # SP0012448

  • Agulnik, Mark (Co-Investigator)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/30/129/22/16

Funding

  • University of Chicago (5-27050 / HHSN261201100071C)